Skip to main content

Table 2 Age distribution of included patients of which test results of all 3 assays are available (n = 11,333).

From: HPV Prevalence in the Dutch cervical cancer screening population (DuSC study): HPV testing using automated HC2, cobas and Aptima workflows

Age (years) Included samples (N) Age distribution of tested cohort (DuSC) Age distribution of Dutch screening population HC2 hrHPV prevalence
%(N)
cobas hrHPV prevalence
%(N)
Aptima hrHPV prevalence
%(N)
Overall hrHPV prevalence
29–33 1,191 10.5% 10.5% 19.1% (228) 19.7% (235) 17.3% (206) 18.7 ± 1.2%
34–38 1,317 11.6% 11.7% 11.7% (154) 11.5% (152) 10.6% (140) 11.3 ± 0.6%
39–43 1,775 15.7% 16.3% 9.0% (159) 8.0% (142) 7.3% (130) 8.1 ± 0.9%
44–48 1,928 17.0% 16.9% 7.7% (148) 7.1% (137) 6.3% (122) 7.0 ± 0.7%
49–53 1,870 16.5% 16.4% 6.3% (117) 5.4% (101) 5.4% (101) 5.7 ± 0.5%
54–58 1,703 15.0% 14.7% 5.4% (92) 5.0% (86) 4.9% (84) 5.1 ± 0.3%
59–63 1,549 13.7% 13.6% 3.9% (61) 4.3% (66) 4.3% (66) 4.2 ± 0.2%
Total (N) 11,333    959 919 849  
  1. Number of included samples per age group and age distribution of study cohort vs age distribution of the Dutch screening program; and hrHPV prevalences per assay and overall mean